 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Eliminationhalf-life | 7–27 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C20H25NO2 |
| Molar mass | 311.425 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Femoxetine (INN; tentative brand nameMalexil; developmental code nameFG-4963) is adrug related toparoxetine that was being developed as anantidepressant by Danishpharmaceutical company Ferrosan in 1975 before acquisition of the company byNovo Nordisk. It acts as aselective serotonin reuptake inhibitor (SSRI). Development was halted to focus attention onparoxetine instead, as femoxetine could not be administered as a daily pill.
Both femoxetine and paroxetine were invented in the 1970s. Jørgen Anders Christensen's name is on the patents[1][2] and Jorgen Buus-Lassen's name is on the pharmacologypaper.[3]
After Ferrosan's acquisition, femoxetine died from neglect.[4]
In a separate patent, Ferrosan stated that Femoxetine could be used as an appetite suppressant,[5] using ten times the dosage than for paroxetine, 300 - 400mg daily.
Femoxetine has the same stereochemical properties asNocaine, another agent with a similar structure claimed to have been synthesized usingarecoline as the starting alkaloid.[citation needed]
 | This sectionmay be too technical for most readers to understand. Pleasehelp improve it tomake it understandable to non-experts, without removing the technical details.(March 2022) (Learn how and when to remove this message) |
Jørgen Buus Lassen femoxetine.
 | Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it. |
